Literature DB >> 33737801

Associations of ARMS2 and CFH Gene Polymorphisms with Neovascular Age-Related Macular Degeneration.

Supanji Supanji1,2,3,4, Dewi Fathin Romdhoniyyah1,2, Muhammad Bayu Sasongko1,2,4, Angela Nurini Agni1,2,4, Firman Setya Wardhana1,2,4, Tri Wahyu Widayanti1,2,4, Muhammad Eko Prayogo1,2,4, Ayudha Bahana Ilham Perdamaian1,2, Aninditta Dianratri1,2, Masashi Kawaichi5, Chio Oka5.   

Abstract

PURPOSE: This study aimed to determine the association of ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H polymorphisms with neovascular age-related macular degeneration (nAMD) for the first time in an Indonesian population. PATIENTS AND METHODS: Our case-control study involved 104 nAMD and 100 control subjects. AMD diagnosis was evaluated by retinal specialists based on color fundus photography and optical coherence tomography. The polymorphisms on CFH Y402H and ARMS2 A69S were analyzed by PCR-restriction fragment length polymorphism (PCR-RFLP), whereas ARMS2 del443ins54 was evaluated by PCR-based assay.
RESULTS: Significant allelic associations with nAMD were detected on all polymorphisms (P<0.05), with stronger association with the ARMS2 A69S (OR 3.13; 95% CI 2.08-4.71; P<0.001) and ARMS2 del443ins54 (OR 3.28; 95% CI 2.17-4.95; P<0.001) polymorphisms than with CFH Y402H (OR 2.08; 95% CI 1.08-3.99; P=0.028). Genotype analysis showed a statistical difference between nAMD and the control group for all polymorphisms (P<0.05). However, the association with nAMD was weaker for CFH Y402H (P=0.043) than for ARMS2 A69S and ARMS2 del443ins54 (P<0.001). A significant interaction between ARMS2 A69S and hypertension was documented (OR 9.53; 95% CI 3.61-25.1; P<0.001).
CONCLUSION: Our findings indicate that ARMS2 A69S and ARMS2 del443ins54 polymorphisms are strongly associated with the risk of nAMD for the first time in an Indonesian population. The risk of nAMD increased when the presence of risk alleles from ARMS2 A69S was combined with the presence of hypertension.
© 2021 Supanji et al.

Entities:  

Keywords:  ARMS2; CFH; age-related macular degeneration; polymorphism

Year:  2021        PMID: 33737801      PMCID: PMC7961131          DOI: 10.2147/OPTH.S298310

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

Age-related macular degeneration (AMD) is a progressive degenerative disease affecting the macula and is the top five leading cause of irreversible blindness worldwide.1 It has been estimated that there are nearly 200 millions of individuals with AMD in 2020, and will be projected to rise to 288 millions in 2040.1 The prevalence of AMD increases exponentially with age.1 With ageing, a cascade of deterioration occurs in photoreceptors, retinal pigment epithelium (RPE) and Bruch’s membrane (BM) leaving permanent lesion observed clinically as geographic atrophy (dry AMD) or causing abnormal blood vessel originating from choroid to leak or to bleed at the macular area (neovascular AMD [nAMD]).2 These may ultimately cause irreversible visual impairment if left untreated. Interestingly, studies showed that not all aged individuals undergo the similar processes and develop AMD, suggesting a strong genetic-driven variation in the pathophysiology of this condition.3 There has been extensive literature reporting the genetic associations in AMD.4–6 Complement Factor H (CFH), Human high-temperature requirement serine protease A1 (HtrA1), and substitution from alanine to serine of amino acid 69 (A69S) in age-related maculopathy susceptibility 2 (ARMS2) at chromosome 10q26 are speculated to play key roles in cellular senescence, thus have been the most consistently associated with AMD in different populations.7–9 In previous studies, ARMS2 and HtrA1 were reported to have a strong linkage disequilibrium.10,11 Grassmann et al12 further asserted that the ARMS2 rs10490924 variant (not HtrA1 rs11200638) is more strongly associated with AMD than HtrA1 rs11200638. This finding was supported by Kanda et al,10 who identify that ARMS2 rs10490924 polymorphism alone can explain the association of the 200-kb region at chromosome 10q26 with AMD. Deletion/insertion consisting of a 443 bp deletion and an adjacent 54 bp insertion in the 3ʹ-untranslated region (3ʹ-UTR) of ARMS2 (del443ins54) and complement factor H Tyr402His (CFH Y402H) was also reported to be strongly associated with AMD.13–15 Deletion/insertion polymorphism in ARMS2 disrupts the stability of ARMS2 gene transcription products16 and induces HtrA1 transcription regulator activity.17 In Western populations, the associations of ARMS2 and CFH were documented in American, Dutch, Italian, Spanish, and Swiss populations.14,18–23 In Asian, similar associations were reported in Chinese, Japanese, and Indian populations.15,24–27 However, very limited evidence is available from Asian Malay population, which is also one of the biggest ethnic groups in Asia. In this study, we aimed to investigate the associations of ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H with AMD in Indonesian population, which constitutes the majority of Asian Malay ethnic group in the region.

Method

This was an age-matched case–control study of participants aged 45 years old or older. Cases were naïve nAMD patients in at least one eye attending retinal clinic at three tertiary hospitals in Yogyakarta: 1) Dr. Sardjito General Hospital; 2) Hardjolukito Military Air Force Central Hospital, and 3) Dr. YAP Eye Hospital with no previous history of AMD treatment, recruited consecutively from August 2016 to November 2018. The diagnosis of AMD was established from slit-lamp examination, fundus photograph and spectral-domain OCT, confirmed by a retinal specialist following the International Age-related Maculopathy (ARM) Epidemiological Study Group28 and AMD clinical classification criteria.29 We excluded cases with co-existing choroidal or other retinal inflammatory diseases. Controls were healthy individuals without AMD or other retinal lesions who underwent eye examination for senile cataract. Each subject was fully informed about the purpose and the procedures of the study. Consent was obtained from all subjects in written form prior to participation. All study procedures adhered to the principles of the Declaration of Helsinki. The study was approved by the Institutional Review Board of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada in August 2016.

Genotyping

The genomic DNA of each patient was extracted from venous blood placed into a tube containing EDTA as an anticoagulant. The blood samples were immediately processed utilizing a commercially available DNA extraction kit (GeneAid Genomic Human DNA Mini Kit [GB100/300], New Taipei City, Taiwan). DNA extraction and single nucleotide polymorphism (SNP) identification were conducted at the Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada. The specific variants for the ARMS2 genes were ARMS2 A69S rs10490924 and ARMS2 del443ins54 (c.*372_815del443ins54), whereas that for CFH Y402H was rs1061170. Polymerase chain reaction (PCR) was performed in a thermal cycler (ProFlex PCR System, Applied Biosystems) following the ready-to-use PCR kit protocol (KAPA Taq PCR Kit, Kapa Biosystems). The PCR cycling conditions were set as follows: 1 cycle (95 °C for 2 min), 30 cycles (95 °C for 30 s), 1 cycle (52 °C for 1 min for each gene), 1 cycle (72 °C for 1 min), and 1 cycle (72 °C for 5 min). The primer sequences for the genes of interest are as follows: 1) ARMS2 A69S forward 5ʹ-TGTCACTGCATTCCCTCCTGTCAT-3ʹ and reverse 5ʹ-AAGCTTCTTACCCTGACTTCCAGC-3ʹ; 2) ARMS2 del443ins54 forward 5ʹ-TACCCAGGACCGATGGTAAC-3ʹ and reverse 5ʹ-GAGGAAGGCTGAATTGCCTA-3ʹ; and 3) CFH Y402H forward 5ʹ-CTTTAGTTCGTCTTCAGTTATAC-3ʹ and reverse 5ʹ-GTCATCTATGTTACTTAGAAAGT-3ʹ. SNP identification involved PCR-based assay for ARMS2 del443ins54 and PCR-restriction fragment length polymorphism (PCR-RFLP) for ARMS2 A69S and CFH Y402H. Restriction digestion was performed at 37 °C for 18 h following the manufacturer’s protocol using PvuII restriction enzyme for ARMS2 A69S (Takara Bio, Japan) and Hsp92II for CFH Y402H (Promega). All amplified products were electrophoresed on 1.5% agarose gel containing FloroSafe DNA stain (1st Base Asia). Random sampling from each genotype in each SNP was conducted for genotype confirmation through Sanger DNA sequencing. Sequencing service was provided by 1st Base Asia, Singapore.

Statistical Analysis

Descriptive data were generated for all variables. Unpaired Student’s t-test for numerical variables or Chi-squared test and Fisher exact test for categorical variables was performed to compare baseline characteristics between nAMD and control groups. Two-sided p-values were reported. We tested for deviation from the Hardy–Weinberg equilibrium (HWE) in both groups through the chi-square test with the “genhwcci” command in Stata. Associations between SNP and other risk factors for susceptibility to nAMD were assessed using logistic regression models measured by odds ratio (OR) and 95% confidence interval (CI). In the multivariable logistic regression model, the likelihood ratio test was performed to fit the model. We pooled one risk allele and two risk alleles as one category (risk allele) in the interaction analysis. Interaction analysis was performed by introducing the interaction term in the same regression model. All analyses were carried out using Stata (version 15.1, StataCorp, College Station, TX, USA).

Results

There were 116 cases [46 males (44.2%) and 58 females (55.8%)] and 100 controls [45 males (45.0%) and 55 females (55.0%)] included in the final analysis. Baseline characteristics of the participants are presented in Table 1. The mean age of cases was 66.3 ± 8.8 years while control was 67.9 ± 7.7 years. Cases showed very similar characteristics to control except that having higher BMI (23.7 vs 22.0; P=0.002) and were more likely to have hypertension (46.2% vs 18.0%; P<0.001) than controls.
Table 1

Baseline Characteristics of Participants

nAMDControlP
(n=104)(n=100)
Age, year
 Range (median)45–83 (67)49–99 (68)0.16
 Mean ± SD66.3 ± 8.867.9 ± 7.7
Sex
 Male46 (44.2%)45 (45.0%)0.91
 Female58 (55.8%)55 (55.0%)
BMI (kg/m2)
 Range (median)15.2–37.1 (23.3)15.2–36.8 (21.4)0.002
 Mean ± SD23.7 ± 3.922.0 ± 4.1
BMI distribution, n
 <18.5 kg/m241 (39.4%)40 (40.0%)<0.001
 18.5–22.9 kg/m26 (5.8%)34 (34.0%)
 23–24.9 kg/m223 (22.1%)16 (16.0%)
 >25 kg/m234 (32.7%)10 (10.0%)
Sunlight exposure
 Indoor workplace73 (70.2%)72 (72.0%)0.78
 Outdoor workplace31 (29.8%)28 (28.0%)
Smoking
 Never73 (70.2%)77 (77.0%)0.27
 Ever31 (29.8%)23 (23.0%)
Blood pressure
 Normal blood pressure56 (53.8%)82 (82.0%)<0.001
 High blood pressure48 (46.2%)18 (18.0%)

Abbreviations: nAMD, neovascular age-related macular degeneration; SD, standard deviation; BMI, body mass index; kg/m2, kilogram/meter2.

Baseline Characteristics of Participants Abbreviations: nAMD, neovascular age-related macular degeneration; SD, standard deviation; BMI, body mass index; kg/m2, kilogram/meter2. The allele/genotype distributions and odds ratio (OR) of each SNP are summarized in Table 2. Significant allelic associations with nAMD were detected on all SNPs (P<0.05). Compared to those having non-risk alleles, those with risk alleles of ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H were more likely to have nAMD (OR 3.13; 95% Confidence Interval [CI] 2.08–4.71 for ARMS2 A69S, OR 3.28; 95% CI 2.17–4.95 for ARMS2 del443ins54, and OR 2.08; 95% CI 1.08–3.99 for CFH Y402H). Genotype analysis showed significant differences between the nAMD and control groups for all polymorphisms (Table 2). The associations of ARMS2 A69S and ARMS2 del443ins54 (P<0.001) with nAMD were stronger than that of CFH Y402H (P=0.043).
Table 2

Case–Control Frequencies of Alleles and Genotypes of SNP on ARMS2 A69S, ARMS2 del443ins54 and CFH Y402H

SNPAllele Distribution (%)Allele Association (P)Crude OR (95% CI)Genotype Distribution (%)Genotype Association (P)Crude OR (95% CI)P (HWE)
CaseControlCaseControl
ARMS2 A69SG61 (29.3%)113 (56.5%)<0.0011.00 (reference)GG16 (15.4%)34 (34.0%)<0.0011.00 (reference)0.398
T147 (70.7%)87 (43.5%)3.13 (2.08–4.71)GT29 (27.9%)45 (45.0%)1.37 (0.64–2.92)
TT59 (56.7%)21 (21.0%)5.97 (2.75–12.96)
ARMS2 del443ins54wt59 (28.4%)113 (56.5%)<0.0011.00 (reference)wt12 (11.5%)32 (32.0%)<0.0011.00 (reference)0.975
indel149 (71.6%)87 (43.5%)3.28 (2.17–4.95)wt/indel35 (33.7%)49 (49.0%)1.90 (0.86–4.21)
indel57 (54.8%)19 (19.0%)7.99 (3.45–18.58)
CFH Y402HT178 (85.6%)185 (92.5%)0.0281.00 (reference)TT75 (72.1%)86 (86.0%)0.0431.00 (reference)0.528
C30 (14.4%)15 (7.5%)2.08 (1.08–3.99)TC28 (26.9%)13 (13.0%)2.47 (1.19–5.11)
CC1 (1.0%)1 (1.0%)1.15 (0.07–18.65)

Abbreviations: HWE, Hardy Weinberg equilibrium in control group; wt (wild-type), non-risk allele; indel, insertion/deletion.

Case–Control Frequencies of Alleles and Genotypes of SNP on ARMS2 A69S, ARMS2 del443ins54 and CFH Y402H Abbreviations: HWE, Hardy Weinberg equilibrium in control group; wt (wild-type), non-risk allele; indel, insertion/deletion. In Table 3, it is shown that homozygous risk allele carriers at the ARMS2 A69S polymorphism (OR 5.97; 95% CI 2.75–13.0) and ARMS2 del443ins54 (OR 7.99; 95% CI 3.45–18.6) were both strongly associated with nAMD. For CFH Y402H, individuals with one copy of the risk allele were more likely to have nAMD than control (OR 2.47; 95% CI 1.19–5.11). These associations remained significant even after controlling for age, gender, smoking, body mass index and blood pressure.
Table 3

Distribution of Unadjusted and Adjusted Odds Ratio for Risk Genotypes in ARMS2 A69S, ARMS2 Del443ins54 and CFH Y402H

Gene (SNP)GenotypeOR (95% CI)POR (95% CI)aPOR (95% CI)bP
ARMS2 A69SGG1.00 (reference)1.00 (reference)1.00 (reference)
GT1.37 (0.64–2.92)0.4151.02 (0.46–2.29)0.9530.76 (0.30–1.94)0.569
TT5.97 (2.75–12.9)<0.0015.89 (2.62–13.3)<0.0016.82 (2.52–18.5)<0.001
ARMS2 del443ins54wt1.00 (reference)1.00 (reference)1.00 (reference)
wt/indel1.90 (0.86–4.21)0.1111.48 (0.65–3.38)0.3550.99 (0.38–2.61)0.994
indel7.99 (3.45–18.6)<0.0017.39 (3.10–17.6)<0.0017.20 (2.56–20.2)<0.001
CFH Y402HTT1.00 (reference)1.00 (reference)1.00 (reference)
TC2.47 (1.19–5.11)0.0152.73 (1.29–5.81)0.0093.84 (1.42–10.4)0.008
CC1.15 (0.07–18.7)0.9230.61 (0.03–12.4)0.7510.94 (0.004–186)0.982

Notes: aAdjusted for age and gender; badditionally adjusted for smoking, body mass index, and blood pressure.

Abbreviations: wt (wild-type), non-risk allele; indel, insertion/deletion.

Distribution of Unadjusted and Adjusted Odds Ratio for Risk Genotypes in ARMS2 A69S, ARMS2 Del443ins54 and CFH Y402H Notes: aAdjusted for age and gender; badditionally adjusted for smoking, body mass index, and blood pressure. Abbreviations: wt (wild-type), non-risk allele; indel, insertion/deletion. In additional analyses, we documented significant interaction between ARMS2 A69S and hypertension. Table 4 shows that individuals who had ARMS2 A69S risk alleles and hypertension had significantly higher odds of nAMD than those with hypertension or ARMS2 A69S risk alleles only (OR 9.53; 95% CI 3.61–25.1; P<0.001).
Table 4

Interaction Analysis of ARMS2 A69S and Hypertension

CategoryOR (95% CI)P-valueOR (95% CI)aP-value
No hypertension & no risk allele1.001.00
Hypertension only3.90 (2.06–7.40)<0.0014.51 (2.31–8.77)<0.001
ARMS2 A69S only2.83 (1.44–5.56)0.0022.81 (1.43–5.56)0.003
Hypertension and ARMS29.53 (3.61–25.1)<0.00110.8 (4.00–28.7)<0.001

Note: aAdjusted for age and gender.

Interaction Analysis of ARMS2 A69S and Hypertension Note: aAdjusted for age and gender.

Discussion

In this study population, we documented that gene polymorphisms of ARMS2 A69S and ARMS2 del443ins54 were strongly and independently associated with nAMD. In contrast, we also documented that the association of CFH Y402H with nAMD was weaker than that of ARMS2 A69S and ARMS2 del443ins54. We also documented a synergistic effect between ARMS2 A69S and hypertension meaning, that individuals with both ARMS2 A69S risk alleles and hypertension had a significantly higher risk of nAMD. Findings from our study reconfirm that ARMS2 genes are strongly associated with nAMD across different populations, at the same time suggest the existence of gene–hypertension interaction between this specific gene and hypertension. We provided the first evidence of the associations of ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H with nAMD in Indonesian population. There have been several studies from Asian population available for direct comparison.15,30–32 ARMS2 A69S gene polymorphisms have been consistently associated with nAMD in Malaysian,33 Chinese Singaporean,31 Thai,30 Chinese,34,35 Japanese,36,37 Korean,38 Indian,32 and European populations.39 It has also been reported that ARMS2 A69S has stronger associations with nAMD than CFH Y402H,40 which is comparable to our study findings. In addition to ARMS2 A69S, results from our study showed that ARMS2 del443ins54, also significantly associated with nAMD, which has been reported in Japanese, Caucasian, and Indian populations.13–15,41 In contrast to ARMS2, associations between CFH Y402H gene variants and nAMD have been less consistent.42 For example, CFH Y402H in Caucasian had a strong association with nAMD,4,14,43,44 but studies from Asian showed a conflicting result. Xu et al,34 Gotoh et al,45 Okamoto et al,46 Uka et al,47 and Chen et al48 showed a weak association of CFH Y402H with AMD while Lau et al49 showed a contradictory result. The role of ARMS2 genes in nAMD has become a subject of interest for more than a decade.10 ARMS2 has been speculated to regulate the surface complement-mediated phagocytosis of cellular debris.50 Micklisch et al50 reported that decreases of the ARMS2 expression in AMD were associated with polymorphism of ARMS2 A69S and del443ins54. Decreases in ARMS2 protein would result in drusen accumulation due to impaired cellular debris clearance.50 Furthermore, a study by Yang and associates51 suggested that ARMS2 A69S risk allele may decrease antioxidant enzyme activity in end-stage AMD-specific induced pluripotent stem cells(iPSCs)-derived RPE model. RPE cells are exposed to intense photo-oxidative energy and excess oxygen, promoting reactive oxygen species (ROS). Decreases in antioxidant enzyme capacity lead to ROS accumulation, increasing oxidative damage contributed to AMD. Some studies have suggested that inflammation may partly explain the link between AMD and ARMS2 polymorphisms.25,52 In iPSCs-derived RPE from AMD donor, Saini et al52 showed that ARMS2 risk allele increased the complement proteins and pro-inflammatory factors compared to iPSCs-RPE derived from healthy control. In addition, there was a study reporting that ARMS2 del443ins54 was correlated with an increase in the serum high sensitivity C-reactive protein (hs-CRP) levels of nAMD subjects in a Japanese study.25 High serum CRP is associated with the late stage of AMD in a systematic literature review and meta-analysis.53 Serum CRP represents systemic inflammatory activity and is a marker of chronic low-grade inflammation.53 The present study also documented gene–hypertension interactions of the ARMS2 A69S and hypertension. Hyman et al54 reported that nAMD and hypertensive disease may have a similar underlying systemic process, as nAMD is linked to high diastolic blood pressure (OR: 4.4; 95% CI: 1.4–14.2). The involvement of oxidative stress accumulation processes in both nAMD and hypertension might explain these associations. The strengths of our study included age-matched cases and controls, detailed clinical and eye examinations by retinal specialist using advanced multimodal imaging to confirm the diagnosis of nAMD and the application of PCR that ensured the accuracy of genetic assessment. However, several limitations were also noted. First, we did not use indocyanine green angiography (ICGA) as the gold standard for nAMD diagnosis. Nevertheless, spectral-domain OCT had high sensitivity and specificity in distinguishing nAMD from polypoidal choroidal vasculopathy (PCV).55–57 Diagnosis of nAMD based on fundus photography and spectral-domain OCT had more than 90% agreement when compared to ICGA,58–60 thus reassuring the minimal bias in this study. Second, the hospital-based design of our study may have only captured the advanced profile of AMD patients, therefore limiting the representation of AMD in general population. Whether or not individuals with AMD from the general population have similar genetic associations remained questionable. Future population-based studies are warranted to address these questions. In conclusion, our study highlighted a strong association of ARMS2 A69S and del443ins54 in people with nAMD in Yogyakarta, Indonesia. This is the first study on nAMD’s genetic risk factors and the first AMD research in Indonesia. Limited studies have been performed in Southeast Asia. Although our study found a weak relationship between the CFH Y402H polymorphism and nAMD risk, further studies are warranted to confirm the relationship of CFH Y402H and nAMD in Indonesian populations. Future work should have larger and more diverse sample sizes to allow subanalysis based on ethnic origin in Indonesia. Genetic information is important in the area of personalized medicine, and it may be useful as a baseline data to establish cohort studies of AMD clinical risk prediction scoring relevant to the Indonesian population.
  59 in total

1.  Genome-wide association study of neovascular age-related macular degeneration in the Thai population.

Authors:  Paisan Ruamviboonsuk; Mongkol Tadarati; Panisa Singhanetr; Sukanya Wattanapokayakit; Punna Kunhapan; Thanyapat Wanitchanon; Nuanjun Wichukchinda; Taisei Mushiroda; Masato Akiyama; Yukihide Momozawa; Michiaki Kubo; Surakameth Mahasirimongkol
Journal:  J Hum Genet       Date:  2017-07-13       Impact factor: 3.172

Review 2.  Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.

Authors:  Mohammad Hossein Jabbarpoor Bonyadi; Mehdi Yaseri; Homayoun Nikkhah; Mortaza Bonyadi; Masoud Soheilian
Journal:  Acta Ophthalmol       Date:  2017-06-08       Impact factor: 3.761

3.  Analysis of the indel at the ARMS2 3'UTR in age-related macular degeneration.

Authors:  Gaofeng Wang; Kylee L Spencer; William K Scott; Patrice Whitehead; Brenda L Court; Juan Ayala-Haedo; Ping Mayo; Stephen G Schwartz; Jaclyn L Kovach; Paul Gallins; Monica Polk; Anita Agarwal; Eric A Postel; Jonathan L Haines; Margaret A Pericak-Vance
Journal:  Hum Genet       Date:  2010-02-25       Impact factor: 4.132

4.  Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration.

Authors:  Yara T E Lechanteur; Patrick L van de Camp; Dzenita Smailhodzic; Johannes P H van de Ven; Gabriëlle H S Buitendijk; Caroline C W Klaver; Joannes M M Groenewoud; Anneke I den Hollander; Carel B Hoyng; B Jeroen Klevering
Journal:  JAMA Ophthalmol       Date:  2015-05       Impact factor: 7.389

5.  Typing of ARMS2 and CFH in age-related macular degeneration: case-control study and assessment of frequency in the Italian population.

Authors:  Federico Ricci; Stefania Zampatti; Francesca D'Abbruzzi; Filippo Missiroli; Claudia Martone; Tiziana Lepre; Ilenia Pietrangeli; Cecilia Sinibaldi; Cristina Peconi; Giuseppe Novelli; Emiliano Giardina
Journal:  Arch Ophthalmol       Date:  2009-10

Review 6.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

Authors:  Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong
Journal:  Lancet Glob Health       Date:  2014-01-03       Impact factor: 26.763

7.  Validation of genome-wide association study (GWAS)-identified disease risk alleles with patient-specific stem cell lines.

Authors:  Jin Yang; Yao Li; Lawrence Chan; Yi-Ting Tsai; Wen-Hsuan Wu; Huy V Nguyen; Chun-Wei Hsu; Xiaorong Li; Lewis M Brown; Dieter Egli; Janet R Sparrow; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2014-02-04       Impact factor: 6.150

8.  Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.

Authors:  Chui M Gemmy Cheung; Timothy Y Y Lai; Kelvin Teo; Paisan Ruamviboonsuk; Shih-Jen Chen; Judy E Kim; Fumi Gomi; Adrian H Koh; Gregg Kokame; Janice Marie Jordan-Yu; Federico Corvi; Alessandro Invernizzi; Yuichiro Ogura; Colin Tan; Paul Mitchell; Vishali Gupta; Jay Chhablani; Usha Chakravarthy; Srinivas R Sadda; Tien Y Wong; Giovanni Staurenghi; Won Ki Lee
Journal:  Ophthalmology       Date:  2020-08-11       Impact factor: 12.079

9.  CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.

Authors:  Demetrios G Vavvas; Kent W Small; Carl C Awh; Brent W Zanke; Robert J Tibshirani; Rafal Kustra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

10.  Association of the del443ins54 at the ARMS2 locus in Indian and Australian cohorts with age-related macular degeneration.

Authors:  Inderjeet Kaur; Stuart Cantsilieris; Saritha Katta; Andrea J Richardson; Maria Schache; Rajeev R Pappuru; Raja Narayanan; Annie Mathai; Ajit B Majji; Nicole Tindill; Robyn H Guymer; Subhabrata Chakrabarti; Paul N Baird
Journal:  Mol Vis       Date:  2013-04-05       Impact factor: 2.367

View more
  3 in total

Review 1.  Molecular Genetic Mechanisms in Age-Related Macular Degeneration.

Authors:  Aumer Shughoury; Duriye Damla Sevgi; Thomas A Ciulla
Journal:  Genes (Basel)       Date:  2022-07-12       Impact factor: 4.141

2.  Association of the HtrA1 rs11200638 Polymorphism with Neovascular Age-Related Macular Degeneration in Indonesia.

Authors:  Supanji Supanji; Ayudha Bahana Ilham Perdamaian; Dewi Fathin Romdhoniyyah; Muhammad Bayu Sasongko; Angela Nurini Agni; Firman Setya Wardhana; Tri Wahyu Widayanti; Muhammad Eko Prayogo; Chio Oka; Masashi Kawaichi
Journal:  Ophthalmol Ther       Date:  2021-11-02

Review 3.  Discovering the Potential of Natural Antioxidants in Age-Related Macular Degeneration: A Review.

Authors:  Kah-Hui Wong; Hui-Yin Nam; Sze-Yuen Lew; Murali Naidu; Pamela David; Tengku Ain Kamalden; Siti Nurma Hanim Hadie; Lee-Wei Lim
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.